  | Willems, M.* , Hamaïdia, M.* , Fontaine, A., Grégoire, M., Halkin, L., Vilanova Mana, L., Terres, R., Jamakhani, M., Deshayes, S., Brostaux, Y., HEINEN, V., LOUIS, R., Duysinx, B., Jean, D., Wasielewski, E., Scherpereel, A., Blanquart, C., & Willems, L. (28 October 2024). The impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivity. EBioMedicine, 109, 105418. doi:10.1016/j.ebiom.2024.105418  Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
Fontaine, A., & Willems, L. (08 February 2024). Metronomic chemotherapy improves the efficacy of immunotherapy in pleural mesothelioma [Paper presentation]. Séminaire Télévie 2024. |
Fontaine, A. (2024). Tumor microenvironment heterogeneity and novel therapeutic approaches in pleural mesothelioma [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/325298 |
Fontaine, A., & Willems, L. (2024). Tumor microenvironment and new therapeutic approaches in pleural mesothelioma [Paper presentation]. GIGA Cancer Seminars, ULiège, Belgique. |
Fontaine, A., & Willems, L. (June 2023). Activation of DNA Damage Tolerance Pathways May Improve Immunotherapy of Mesothelioma [Poster presentation]. International Mesothelioma Interest group Conference. Editorial reviewed |
 | Willems, M., Scherpereel, A., Wasielewski, E., Raskin, J., Brossel, H., Fontaine, A., Grégoire, M., Halkin, L., Jamakhani, M., Heinen, V., Louis, R., Duysinx, B., Hamaïdia, M.* , & Willems, L.*. (2023). Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma. Frontiers in Immunology, 14, 1148798. doi:10.3389/fimmu.2023.1148798 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
Fontaine, A., & Willems, L. (08 April 2022). Activation of DNA Damage Tolerance Pathways May Improve Immunotherapy of Mesothelioma [Poster presentation]. Séminaire Télévie 2022. |
 | Hoyos, C.* , Fontaine, A.* , Jacques, J.-R., Heinen, V., Louis, R., Duysinx, B., Scherpereel, A., Wasielewski, E., Jamakhani, M.* , Hamaïdia, M.* , & Willems, L.*. (2022). HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells. Cancers, 14 (9), 2164. doi:10.3390/cancers14092164 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Hoyos, C., Fontaine, A., Brossel, H., Willems, M., Jamakhani, M., Vandermeers, F., Safari, R., HEINEN, V., LOUIS, R., DUYSINX, B., Scherpereel, A., Wasielewski, E., Mascaux, C., Hamaïdia, M.* , & Willems, L.*. (14 December 2021). Contribution of lysine deacetylases to the therapy of malignant pleural mesothelioma [Poster presentation]. Giga Cancer Day, Liège, Belgium. * These authors have contributed equally to this work. |
 | Willems, M., Jamakhani, M., Scherpereel, A., Wasielewski, E., Brossel, H., Fontaine, A., Hoyos, C., Grégoire, M., Louis, R., Duysinx, B., Hamaïdia, M.* , & Willems, L.*. (14 December 2021). Eosinophils inhibit malignant pleural mesothelioma response to chemotherapy [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. * These authors have contributed equally to this work. |
 | Brossel, H.* , Fontaine, A.* , Hoyos, C.* , Jamakhani, M.* , Willems, M.* , Hamaïdia, M., & Willems, L. (2021). Activation of DNA Damage Tolerance Pathways May Improve Immunotherapy of Mesothelioma. Cancers, 13, 3211. doi:10.3390/cancers13133211 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
